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MDAAbstract Aim: To study the effect of alkylating agents such as EMS and MMS on chromosomes
and biochemical parameters in induced diabetic mouse.
Methods: Chromosome preparations from bone marrow was made using the method of Evans
et al. (1964) and biochemical estimations from the liver was done by the method of Sinha (1972) for
catalase, Van der Vies (1954) for glycogen and Uchiyama and Mihara (1978) for MDA.
Results: The study has revealed that EMS and MMS induced a dose dependent increase in
chromosomal aberrations of chromatid type in the diabetic mouse. Nonetheless, it is interesting
to note that, there is signiﬁcant reduction in the frequency of chromosomal aberrations in diabetic
compared to non diabetic mice at all tested doses of EMS or MMS and at different recovery times
[RTs]. On the other hand biochemical parameters showed a variable degree of reactivity: (1)
catalase activity was signiﬁcantly elevated in non diabetics whereas in diabetics it is signiﬁcantly
decreased with increasing concentrations of EMS. Contrary to this, the catalase activity in the case
of MMS treatment is signiﬁcantly reduced in non diabetics compared to diabetic mice. (2) However
glycogen level is signiﬁcantly reduced in both the diabetic and non diabetic with increasing concen-
trations of EMS or MMS, but MDA levels were signiﬁcantly increased.
Conclusion: (1) Even though alkylating agents induce chromosomal aberrations in diabetic mice,
MMS, a methylating agent is a more potent inducer of chromatid type of aberrations than EMS, an
ethylating agent. (2) Diabetic mouse is more resistant than the non diabetic to alkylating agents and
(3) the tested agents altered the analyzed biochemical parameters.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).rbituric
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Diabetes is one among the top ten leading killers of human
population which is characterized by the deﬁciency in insulin
production or inability of cells to detect insulin, resulting in
increased blood glucose [1]. It was reported that about 382 mil-
lion people are suffering from diabetes around the world and
expected to reach 592 million by 2035 (World Diabetic
Congress, 2013). About 26.9% of all people over 65 years have
diabetes and 60% have cancer. Overall, 8–18% of cancer
patients have diabetes [1]. Epidemiological studies of Lee
et al. [2,3] have revealed that the incidence of diabetes has
increased due to exposure to pollutants. Alkylating agents
are one such group of pollutants which are affecting the
genetic systems of animals including humans [4] on the one
hand, and on the other, these are being used as anticancer
agents [5]. Even though, alkylating agents are being extensively
used for cancer treatment, their inﬂuence in diabetic conditions
in humans in particular or other animal systems in general has
not been worked out. In vivo human as test system cannot be
used; hence mouse as model for diabetic condition has been
employed to understand the inﬂuence of alkylating agents. It
is worthy to mention that, there are extensive reports on the
induction of chromosomal aberrations by alkylating agents
in various in vivo test systems like Yeast [6], Plant [7,8],
Drosophila [9], Poecilocerus pictus [10], non diabetic mouse
[11,12], non diabetic rats [13] and in vitro test systems like
Chinese hamster ovary cells [14,15] and Human lymphocytes
[16,17]. Mahadimane and Vasudev [18,19] working in in vivo
Ehrlich ascites, a disease condition, have demonstrated a dose
dependent increase in clastogenicity using MMS or EMS.
Though voluminous reports on the effects of alkylating agents
in normal conditions are available, there is no literature as far
as we know on diabetic animal systems. Hence, the present
studies were undertaken to understand the inﬂuence of mono
functional alkylating agents, such as EMS and MMS on chro-
mosomes and biochemical parameters in induced diabetic
mice.2. Materials and methods
2.1. Chemicals
Alkylating agents, EMS (CAS number 62-50-0) and MMS
(CAS Number 66-27-3) were purchased from Sigma Co. St.
Louis, MO, USA and colchicine (CAS No. 64-86-8) from
Himedia Pvt Ltd., Mumbai, India. Giemsa stain and other
chemicals were of analytical grade commercially available.
Streptozotocin (STZ) (CAS No. 18883-66-4) was purchased
from SRL, Mumbai, India.
2.2. Animals
Male Swiss albino mice weighing 25–30 g of 6–8 weeks old
were used. The mice were maintained in the laboratory,
Department of Studies in Zoology, University of Mysore,
Mysore, housed in polypropylene cages which were provided
with standard feed pellets and water ad libitum under 12 h
light/dark cycle. The study was approved by the Institutional
animal ethics committee and the work was carried out inaccordance with The Code of Ethics of The World Medical
Association for experiments in animals.
2.3. Induction of diabetes in mouse
Diabetes was induced by injecting a single intra peritoneal dose
of STZ (180 mg/kg body weight) (Freshly prepared in 0.1 M
citrate buffer pH 4.5) as described by Yanardag et al. [20].
The control mice were given 0.5 ml of citrate buffer. Prior to
administration, mice were fasted for 4 h but were given water
ad libitum. Animals were kept under observation for 5 days fol-
lowing administration and blood glucose concentration was
measured by SD check glucometer, Japan. On the ﬁfth day
mice with blood glucose levels above 300 mg/dl and below
400 mg/dl were used in the present studies as type I diabetic
mouse [21].
2.4. Treatment schedule
Diabetic and non diabetic mice were grouped into six (A–F) in
MMS and eight (A–H) groups in the case of EMS and each
group consists of 3 mice. Diabetic and non diabetic mice were
injected with 0.5 ml saline containing different concentrations
of EMS (50, 100, 200, 250, 300, 350 and 400 mg/kg body
weight) or MMS (35, 70, 105, 140, 175 mg/kg body weight).
The controls received only 0.5 ml of saline. Animals were killed
at 24, 48 and 72 h recovery times (RTs) and further processed
for different parameters.
2.5. Mitotic chromosome preparation
90 min before killing, the treated animals were injected
intraperitonealy with 0.5 ml of 0.05% Colchicine. Bone mar-
row was extracted and slides were prepared by a routine air
dry technique [22]. These air- dried slides were coded and
stained with 4% Giemsa for 20–30 min. Non-overlapping
metaphase plates were scored for chromosomal aberrations
such as chromatid breaks, chromatid exchanges,
intra-chromatid deletions, triradials, chromosome breaks,
dicentrics, rings, and minutes. 100 well spread metaphase
plates were scored for each animal and experiments were
repeated thrice.
2.6. Biochemical assays
After killing the animals at different RTs, the liver was dis-
sected for biochemical assays such as catalase, glycogen and
Malondialdehyde (MDA).
2.6.1. Activity of catalase (EC 1.11.1.6)
The activity of catalase was measured in liver homogenate by
the method of Sinha [23]. The enzyme extract was added to the
reaction mixture containing 1 ml of 0.01 M phosphate buffer
(pH 7.0) and 0.5 ml of 0.2 M H2O2 for 30 s. The reaction
was terminated by the addition of dichromate acetic acid.
The formed chromic acetate was measured at 590 nm.
2.6.2. Estimation of glycogen
Total glycogen content was estimated according to the method
of Van der Vies [24]. In brief, liver homogenate was prepared
Table 1 Percentage frequency of chromosomal aberrations (Mean ± SE) induced by different doses of EMS in non diabetic a d diabetic mice recovered after 24 h.
Dose (mg/kg body wt) B0 B00 RB0 RB0B00 ID Ring Minutes Chromosomal aberration Total number of breaks
Control I Non diabetic 1.67 ± 0.19 0.56 ± 0 1 2.22 ± 0.22 2.22 ± 0.22a
Control II Diabetic 1.22 ± 0.22 0.11 ± 0.11 1.11 ± 0 2 2.45 ± 0.40 2.56 ± 0.44a
50 Non diabetic 1.33 ± 0.38 0.33 ± 0.00 1.22 ± 0 1 2.89 ± 0.29 3.22 ± 0.29a
Diabetic 1.11 ± 0.22 0.44 ± 0.29 1.56 ± 0 1 3.11 ± 0.11 3.56 ± 0.29a
100 Non diabetic 11.22 ± 0.40 1.56 ± 0.29 0.67 ± 0.19 0.11 ± 0.11 6.11 ± 0 7 19.67 ± 1.35 22.00 ± 1.90b
Diabetic 6.33 ± 0.38 0.67 ± 0.19 0.22 ± 0.11 4.34 ± 0 8 11.56 ± 1.28 12.44 ± 1.42c
200 Non diabetic 21.89 ± 2.92 3.33 ± 0.33 1.22 ± 0.40 0.89 ± 0.29 0.33 ± 0.19 12.56 ± 1 6 40.22 ± 2.06 46.89 ± 2.61d
Diabetic 12.22 ± 0.64 1.78 ± 0.24 0.56 ± 0.09 0.11 ± 0.09 0.33 ± 0.16 9.89 ± 0 9 24.89 ± 1.18 27.67 ± 1.40e
250 Non diabetic 35.33 ± 2.65 5.11 ± 0.40 1.00 ± 0.39 0.33 ± 0.19 0.33 ± 0.00 0.11 ± 0.11 18.56 ± 0 8 60.78 ± 3.85 68.00 ± 4.55f
Diabetic 20.33 ± 1.58 2.44 ± 0.29 0.67 ± 0.19 0.45 ± 0.22 0.33 ± 0.19 0.78 ± 0.11 16.00 ± 1 5 41.00 ± 0.51 46.11 ± 0.87d
300 Non diabetic 48.44 ± 2.60 7.22 ± 0.73 2.44 ± 0.48 0.78 ± 0.11 0.45 ± 0.22 0.33 ± 0.19 28.22 ± 2 0 87.89 ± 0.73 99.89 ± 1.37g
Diabetic 24.44 ± 1.44 4.44 ± 0.44 0.44 ± 0.29 0.56 ± 0.29 0.33 ± 0.19 0.45 ± 0.22 27.56 ± 2 5 58.22 ± 1.64 65.00 ± 1.35f
Note: Pooled data from three independent experiments; 900 cells were analysed per dose; 3 animals were used for each treatment. B0 – Chro atid breaks; B00 – Isochromatid breaks; RB0 – Chromatid
exchange; RB0B00 – Triradials; ID – Intrachromatid deletion. Values with same superscripts are not signiﬁcant (p> 0.05); values with fferent superscripts are signiﬁcantly different from one
another (p< 0.05) according to Duncan Post hoc test.
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304 B.B.D. Khalandar, V. Vasudevin 10 ml of 4% TCA and centrifuged at 3000 rpm for 10 min.
To the supernatant, 4 ml of anthrone reagent was added. Then
test tubes were cooled to room temperature and OD was mea-
sured at 620 nm against the blank.
2.6.3. Estimation of Malondialdehyde
The concentration of Malondialdehyde (MDA) was deter-
mined as lipid peroxidation index using the method of
Uchiyama and Mihara [25]. Brieﬂy, liver homogenate was
mixed with trichloroacetic acid (20%) and the precipitate
was dispersed by H2SO4 (0.05 M). Then, TBA (0.2% in 2 MTable 2 Percentage frequency of chromatid aberrations (Mean ± SE
mice recovered after 24, 48 and 72 h.
Treatment in mg/kg bw. Chro
24 h
Control I Non diabetic 2.2
Control II Diabetic 2.3
50 Non diabetic 2.5
Diabetic 2.6
100 Non diabetic 17.3
Diabetic 10.6
200 Non diabetic 34.4
Diabetic 22.1
250 Non diabetic 53.8
Diabetic 36.3
300 Non diabetic 76.6
Diabetic 52.0
Note: Pooled data from three independent experiments; 900 cells were an
same superscripts are not signiﬁcant (p> 0.05); values with different
according to Duncan Post hoc test.
a–h have been used to distinguish different values with statistical signiﬁca
Table 3 Percentage frequency of chromatid aberrations (Mean ±
diabetic mice recovered after 24, 48 and 72 h.
Treatment in mg/kg bw. Chromat
24 h
Control I Non diabetic
Control II Diabetic
35 Non diabetic
Diabetic
70 Non diabetic
Diabetic
105 Non diabetic
Diabetic
140 Non diabetic
Diabetic
175 Non diabetic Animals
Diabetic
Note: Pooled data from three independent experiments; 900 cells were an
same superscripts are not signiﬁcant (p> 0.05); values with different
according to Duncan Post hoc test.sodium sulphate) was added and heated for 30 min in boiling
water bath. To this, 3 ml n-butanol is added which gives pink
color at the upper layer. This pink colored solution was aspi-
rated and absorbance was measured at 532 nm.
2.7. Statistical analyses
The data were expressed as Mean ± S.E and compared using a
one way analysis of variance (ANOVA). Comparisons among
groups were made according to Duncun’s post hoc comparison
test. Signiﬁcance level was p< 0.05.) induced by different doses of EMS in non diabetic and diabetic
matid aberrations
48 h 72 h
3 ± 0.30a 2.23 ± 0.30a 2.22 ± 0.22a
3 ± 0.29a 2.33 ± 0.29a 2.33 ± 0.29a
5 ± 1.10a 2.22 ± 0.44a 2.00 ± 0.11a
7 ± 1.40a 2.66 ± 0.40a 2.77 ± 0.22a
3 ± 0.88b 15.33 ± 1.26b 10.56 ± 0.11b
7 ± 0.40c 10.00 ± 0.88c 9.44 ± 0.81b
5 ± 1.10d 26.55 ± 1.69d 18.00 ± 0.22c
1 ± 2.23e 18.00 ± 0.77e 14.12 ± 0.22d
9 ± 1.40f 36.67 ± 2.80f 24.11 ± 0.33e
3 ± 0.89d 23.55 ± 1.92d 16.22 ± 0.44f
6 ± 3.67g 66.00 ± 7.27g 40.55 ± 0.66g
0 ± 2.2f 32.34 ± 1.95h 24.88 ± 0.88e
alysed per dose; 3 animals were used for each treatment. Values with
superscripts are signiﬁcantly different from one another (p< 0.05)
nce.
SE) induced by different doses of MMS in non diabetic and
id aberrations
48 h 72 h
2.22 ± 0.22a 2.22 ± 0.22a 2.22 ± 0.22a
2.33 ± 0.29a 2.44 ± 0.29a 2.44 ± 0.18a
15.34 ± 0.95b 12.44 ± 0.59b 6.89 ± 0.22b
11.22 ± 0.68b 8.56 ± 0.40b 6.22 ± 0.45b
33.11 ± 1.11c 25.01 ± 0.67c 18.44 ± 1.25c
23.11 ± 1.22d 17.89 ± 0.89d 18.39 ± 0.33d
49.89 ± 1.66e 39.56 ± 3.48e 32.45 ± 1.07e
37.45 ± 0.44f 28.33 ± 0.89c 21.67 ± 0.51f
67.22 ± 2.45g 53.23 ± 1.85f 43.33 ± 0.89g
49.33 ± 1.35e 39.22 ± 0.44e 20.00 ± 0.71e
death
88.00 ± 1.97h 66.44 ± 2.47g 52.11 ± 1.64h
alysed per dose; 3 animals were used for each treatment. Values with
superscripts are signiﬁcantly different from one another (p< 0.05)
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3.1. Mortality with the treatments of EMS or MMS
Non diabetic mice treated with 400 mg/kg body weight of
EMS and 175 mg/kg body weight of MMS did not survive
up to 24 h, while the diabetic mice survived.
3.2. Clastogenic effect of EMS and MMS
The results of treatments with different concentrations of EMS
ranging from 50 to 300 mg/kg body weight or 35–175 mg/kg
body weight of MMS in diabetic and non diabetic mice with
respective controls are presented in Tables 1–3. Diabetic (con-
trol II) and non diabetic (control I) mice without chemical
treatment showed almost similar chromosomal aberrations.
Similarly, the lowest dose of EMS employed (50 mg/kg body
weight) could not produce signiﬁcant chromosomal aberra-
tions (p> 0.05), whereas, 100 mg/kg body weight and the
above tested doses induced signiﬁcant dose dependent
increases in chromosomal aberrations in both categories of
mice at all RTs tested (p< 0.05, Tables 1 and 2). Fig 1a shows
a linear signiﬁcant decrease in chromosomal aberrations from
the ﬁrst RT to last RT except the lowest dose in non diabeticFigure 1 Percentage of chromosomal aberrations at different doses of
Note: Pooled data from three independent experiments; 3 animals wermice, whereas, in diabetics (Fig 1b), only higher doses such as
200, 250 and 300 mg/kg body weight of EMS showed signiﬁ-
cant decreases in chromosomal aberrations (p< 0.05).
Signiﬁcant dose dependent increases in the frequency of
chromosomal aberrations up to 140 mg/kg body weight
induced by MMS in non diabetic and diabetic mice were
observed at all tested RTs compared to controls (Table 3)
(p< 0.05). 127.33%, 91.89% and 63% chromosomal
aberrations were noticed at 175 mg/kg body weight in diabetic
mice at 24, 48 and 72 h RTs respectively (Table 3) and were
signiﬁcant compared to controls (2.22%) (p< 0.05). A linear
signiﬁcant decrease in chromosomal aberrations was noticed
from 24 to 72 h RT after treatment with respective doses in
both non diabetic and diabetic (p< 0.05, Fig 2a and b).
EMS or MMS treated diabetic mice showed signiﬁcant
reduction in chromatid aberrations after 24, 48 and 72 h RTs
compared to their respective doses in non diabetics (Table 2
and 3) (p< 0.05) except lower doses.
3.3. Biochemical assays
3.3.1. Catalase activity
The catalase activity is decreased in a dose dependent manner
in diabetic mice treated with EMS except at 24 and 48 h RTs ofEMS (a) non diabetic (b) diabetic mice recovered at different RTs.
e used for each treatment.
306 B.B.D. Khalandar, V. Vasudev50 and 100 mg/kg body weight. In non diabetics the results are
in contrast to the diabetic. In both diabetic and non diabetic,
at 72 h RT, EMS could not signiﬁcantly alter the catalase
activity at different dose levels (Fig. 3a).
However in diabetic mouse, MMS caused an increase in
catalase activity in a dose dependent manner at 24 h RT,
except the lowest dose. In contrast, to this, in non diabetic
mice, there is a decrease in activity. On the other hand at 48
and 72 h RTs there is not much variation in activity in both
diabetic and non diabetic mice (Fig 3b).
3.3.2. Glycogen content
Among the controls, the non diabetic control (16.2 lg/g)
showed signiﬁcantly high glycogen levels compared to diabet-
ics (10.3 lg/g). In the treatment schedules, there is signiﬁcant
reduction in glycogen levels at all tested doses except 50 mg/kg
body weight at 72 h RTs in non diabetic and at higher doses of
200, 250, and 300 mg/kg body weight of EMS of diabetic mice
at all tested RTs compared to respective controls (p< 0.05)
(Fig 4a).
Contrary to this, no reduction in glycogen levels was seen
when MMS was treated to diabetic mice at lower doses such
as 35, 70 and 105 at 24 h and 35, and 70 at 48 h and all tested
doses at 72 h RTs. In non diabetic mice MMS treatmentFigure 2 Percentage of chromosomal aberrations at different doses
RTs. Note: Pooled data from three independent experiments; 900 cellssigniﬁcantly reduced glycogen levels at 24 h and 48 h RT at
all tested doses except for 35 mg/kg body weight at 48 h RT
(Fig 4b).
3.3.3. Malondialdehyde level
MDA level was signiﬁcantly elevated in diabetic (control II)
compared to non diabetic (control I) mice. Similarly, in the
treatments also both EMS and MMS showed signiﬁcant
increases in MDA levels in non diabetic and diabetic mice at
different RTs, except all tested doses at 72 h and the lowest
dose at 24 and 48 h of diabetic mice, while in non diabetic only
the lowest dose at 48 and 72 h in the case of EMS and 24 and
72 h in MMS treatments were insigniﬁcant (p> 0.05 Fig 5a
and b).
4. Discussion
EMS and MMS induced signiﬁcant chromosomal aberrations
in both diabetic and non diabetic mice (p< 0.05) (Figs 1 and
2). These results are on par with the data of earlier workers
where they have demonstrated the induction of chromosomal
aberrations by employing the said agents in varied test systems
and majority of aberrations were of chromatid type induced by
EMS or MMS [8,26–29]. Further, dose dependent induction ofof MMS (a) non diabetic (b) diabetic mice recovered at different
were analysed per dose; 3 animals were used for each treatment.
Dose response relationship by EMS and MMS in diabetic mouse 307aberrations was noticed in the present investigation in diabetic
and non diabetic mice as has been observed by earlier workers
[27,30]. Even though, chromatid aberrations were produced in
diabetic and non diabetic mice, it is interesting to note that the
percentage of chromatid aberrations was less in diabetic than
non diabetic mice. For example 300 mg/kg body weight of
EMS induced 52% of chromatid aberrations in diabetic mice
and 76% in non diabetic and 140 mg/kg body weight of
MMS induced 49% of chromatid aberrations in diabetic and
67% in non diabetic mice. As far our knowledge goes, it is
the ﬁrst report on the induction of chromatid aberrations in
diabetic mice in general and signiﬁcantly less than non diabetic
in particular. Thus, in the present study diabetic mice showed
resistance to EMS or MMS induced chromosomal aberrations.
This type of resistance of the diabetic mouse to alkylating
agents can be viewed from the hypothesis that short term star-
vation (48–60 h) or low glucose can protect mammalian cells
against damaging effects of high doses of chemotherapy.
Raffaghello et al. [31] tested the effect of normal glucose
(1.0 g/L), low glucose (0.5 g/L) and high glucose (3.0 g/L) on
H2O2 treatment in rat glial cells. The results have revealed that
80% of rat glial cells pretreated with normal and low glucose
were resistant, while only 10% of cells pretreated with high
glucose survived. However, cytotoxicity of H2O2 towardFigure 3 Catalase activity in the liver of mice at different RTs (
experiments; 3 animals were used for each treatment. ND – Non diabe
hoc test between diabetic and non diabetic groups, values with di
(p< 0.05).cancer cells was unaffected. In the similar experiment, 80%
of glial cells were resistant to 12 mg/ml cyclophosphamide
(CP-widely used in cancer treatment) in the presence of
0.5 g/lt glucose, whereas only 20% of the cells survived this
treatment in 1 g/lt glucose [31]. When another widely used
chemotherapeutic drug namely etoposide (damage DNA and
cause toxicity) was used, 80 mg/kg killed 43% of control mice
by day 10; but only 1% of the mice that were pre-starved died
after etoposide treatment [31]. Thus, it was concluded that
short term starvation greatly improves early survival by ame-
liorating chemotherapy toxicity. When yeast cells were cul-
tured in low glucose media and treated with MMS, they
showed increased survival rate [32], demonstrating that low
glucose has reduced glycolytic rate, resulting in repression of
respiration and TCA enzymes, and increased citrate synthase
activity, as a consequence pyruvate is utilized more effectively
in mitochondria, enabling NADH production in TCA and
NAD+ regeneration, which could serve as a protective mech-
anism against MMS, enabling more cells to survive. In the case
of Escherichia coli, prior to MMS treatment cells cultured in
0.2% and 0.4% of glucose showed an increased survival rate
compared to cells cultured in normal media [33] and, termed
it as ‘‘Glucose induced resistance (GIR)’’, proposing that
GIR is a consequence of enhanced repair capability involvinga) EMS (b) MMS. Note: Pooled data from three independent
tic, D – Diabetic. Statistical analysis was done using Duncan Post
fferent superscripts are signiﬁcantly different from one another
308 B.B.D. Khalandar, V. Vasudevat least some of the gene products of the Rec system. Bjorkhem
[34] has studied the inhibition of x oxidation of long chain
fatty acid in the normal, starved and diabetic rat liver and con-
cluded that x oxidation is inhibited in normal rat liver cells
where as in diabetic and starvation state this inhibition is
released. Thus they concluded that the physiological condition
of both diabetic and starved state is utmost important. In the
case of starvation cells depend upon an endogenous source and
undergo gluconeogenesis for energy [35,36]. Even under dia-
betic conditions, cells depend upon endogenous sources by
accelerating gluconeogenesis and a decrease in glycolysis [cf.
37], but these cells cannot utilize the external glucose for
energy [38]. With these lines of evidence, it can be opined that
the physiological condition of both starved and diabetic cells
are the same and thus in the present study decreased chromatid
aberrations in EMS or MMS treated diabetic mice might be
because of altered metabolic pathways as of starved cells.
The results of the present study show that a relatively low
dose of MMS is sufﬁcient to induce signiﬁcant chromosomal
aberrations in comparison to EMS in diabetic and non
diabetic mice. This points out that MMS is a more potent
inducer of chromosomal aberrations in diabetic and non dia-
betic mice. Similarly, Riaz Mahmood [27] working on normal
(non diabetic) mitotic cell of mouse; Sega and Owens [39] on
normal mouse germ cells; Rao and Natarajan [40] using
Vicia faba; Siddique et al. [5] in Drosophila; Riaz Mahmood
and Vasudev [10] in P. pictus; Vogel and Natarajan [cf. 26]
in CHO cells and Harish et al. [17] employing HumanFigure 4 Glycogen levels in the liver of mice at different RTs (a) EMS
3 animals were used for each treatment. ND – Non diabetic, D – Diabe
diabetic and non diabetic groups, values with different superscripts arlymphocytes have demonstrated the potency of MMS to
induce more chromosomal aberrations than EMS. The postu-
lated reasons can be that (1) EMS is an ethylating agent and
MMS is a methylating agent and thus methylating agent
may be a potent inducer of chromosomal aberrations in mice
than ethylating agent. (2) Swain scott constant (s) value of
MMS is high (0.83) compared to EMS (0.67). Using the same
equation, in in vivo systems such as V. faba and Drosophila,
Rao and Natarajan [40] and Vogel and Natarajan [41]
respectively have demonstrated that alkylating agents with high
s-value were found to be more cytotoxic and less mutagenic
than with low s value. Thus present results also underline
the importance of s value in the induction of chromosomal
aberrations whether diabetic or non diabetic mice.
There is reduction in the frequency of aberrations from 24
to 72 h RTs with EMS or MMS in diabetic and non diabetic
mice. This is on par with Obe and Beek [42], where they
observed a decreased aberration frequency with an increase
in culture time in human lymphocytes reﬂecting a mechanism
of ‘mitotic selection’ of aberration bearing cells. Similar obser-
vations in non diabetic mice were also made by Riaz
Mahmood [27].
Working on rat liver catalase activity under the inﬂuence of
chlorfenvinphos (CVP), an organophosphate insecticide,
Lukaszewich-Hussain and Moniusko-Jakoniuk [43] showed
the increased activity at 1st h at the dose of 0.2 LD50 and 1st
and 24 h at the dose of 0.1 LD50. Similarly, in the present study
in non diabetic mice, the activity of catalase tended to increase(b) MMS. Note: Pooled data from three independent experiments;
tic. Stastical analysis was done using Duncan Post hoc test between
e signiﬁcantly different from one another (p< 0.05).
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this, the results were vice versa in diabetic mice. In the case
of MMS treatment catalase activity increased in diabetic mice
and decreased in non diabetic at 24 h RTs. However, with
EMS at 72 h RT and MMS at 48 and 72 h in both diabetic
and non diabetic mice with different doses, the activity of cata-
lase did not exhibit signiﬁcant changes, thus, it can be opined
that the changes in the activity of catalase were not dose
dependent. Working in non diabetic mice Guruprasad et al.
[44] have demonstrated an increase in catalase activity with
EMS and decreased activity with MMS treatment which is
on par with our studies in non diabetic mice. Salmon et al.
[45] and Friedberg et al. [46] have showed that MMS cannot
produce ROS directly, but induced the DNA damage causing
an increase in intracellular ROS level in yeast cells.
Cyclophosphamide treatment has shown decreased catalase
activity in the liver and lung of mice [47] and with
Chlorambucil in the rat liver [48]. When HL-60 cells were trea-
ted with alkylating agents such as melphalan and
Chlorambucil an increase in intracellular peroxide was
reported. This increase in peroxide was time and concentration
dependent that induced apoptosis. Pre treatment of HL-60
cells with catalase provided partial protection against low con-
centration of melphalan, whereas Chlorambucil could not
induce protection against apoptosis, suggesting that hydrogenFigure 5 MDA levels in the liver of mice at different RTs (a) EMS (b
animals were used for each treatment. ND – Non diabetic, D – Diabet
diabetic and non diabetic groups, values with different superscripts arperoxide is not the main peroxide produced by Chlorambucil
treatment [49]. At this juncture it is pertinent to mention that
there are few data concerning the inﬂuence of alkylating agents
on the activity of catalase and for this reason it is difﬁcult to
compare our results with those reported by other authors.
The interpretation of the decrease and increase in the catalase
activity is difﬁcult as has been discussed by Lukaszewich-
Hussain and Moniusko-Jakoniuk [43], even though, the
increase in activity can be explained as the response of the liver
to high levels of H2O2. The decreased activity of catalase may
be because of the inhibition of catalase activity by superoxide
anion as has been proposed by Laszlo et al. [50].
Glycogen is the polymer of glucose which is known as ani-
mal starch and it is the most readily available source of energy
in the animal tissues. In the present studies both diabetic and
non diabetic mice have a decreased glycogen content.
However, it is beﬁtting to note that between diabetic and
non diabetic, a signiﬁcant decrease is observed in treated dia-
betic mice. Mancozeb and carbofuran pesticides have
increased the level of glycogen [51,52]. Carbosulfan caused
decreased glycogen with increasing dose exposure [53].
Treatment with diethylnitrosamine (DENA) and dimethylni-
trosoamine (DMNA) [54] has reduced liver glycogen in the
rat. Dermal application of sulfur mustard has reduced the
glycogen content in the liver [55]. In our study a greater) MMS. Note: Pooled data from three independent experiments; 3
ic. Stastical analysis was done using Duncan Post hoc test between
e signiﬁcantly different from one another (p< 0.05).
310 B.B.D. Khalandar, V. Vasudevreduction in liver glycogen was observed in EMS than in MMS
in both diabetic and non diabetic mice. Decreased levels of
glycogen may be due to either an increased catabolism of the
biomolecules to meet the enhanced energy demand of animals
under stress or their reduced synthesis due to impaired tissue
function [56].
When antioxidants are no longer capable of coping with
ROS, results in oxidative stress in turn affect cellular integrity.
This ROS reacts with the unsaturated fatty acid of cellular or
sub cellular membranes and they lead to peroxidation of mem-
brane lipids. The oxidative stress caused by different agents is
often estimated by the level of MDA [57]. Diabetic mice
showed increased lipid peroxidation compared to non diabetic
and the reason might be due the variation in lipid metabolism
[58] which alters the function of cellular membrane, inhibiting
the activity of superoxide dismutase enzyme leading to accu-
mulation of superoxide radicals resulting in maximum lipid
peroxidation and tissue damage in diabetes [59], also increased
glycation of protein in diabetes mellitus. The glycated protein
might themselves act as a source of free radicals. There is a
clear association between lipid peroxide and glucose concen-
tration, which may be also thought to play a role in increased
lipid peroxidation in diabetes mellitus [60]. The results after the
treatment with EMS or MMS in both diabetic and non diabet-
ics showed enhanced levels of MDA at 24 h RT. Further it is
interesting to note that level of MDA decreased with increas-
ing time. Lukaszewich-Hussain and Moniusko-Jakoniuk [43]
demonstrated the increased MDA level at 48th h after intoxi-
cation with CVP at a dose of 0.5 LD50 and as early as at 1 h
after intoxication with two lower doses of insecticide. At
24 h of intoxication with insecticide of 0.5 LD50, a decreased
MDA level was observed. This along with our results, indicate
that the prooxidant effect of the highest dose of agents
becomes signiﬁcant only after later time of intoxication, while
the same effect of lower doses is evident much earlier.
Eventhough, there are no reports on the effect of alkylating
agents on MDA levels, the increased level of MDA in intoxi-
cation with organophosphate insecticide has been reported
[61,62]. A dose-dependent increase in MDA concentration
was found in the renal tubules of rats after treatment with ace-
phate [63]. The MDA concentration was increased also in the
skeletal muscles of rats intoxicated with diisopropylﬂuo-
rophosphate [50]. Treatment with Chorambucil induced the
lipid peroxidation in rat liver [48]. In mice, lipid peroxidation
was increased in the liver and lung treated with
Cyclophosphamide [47]. In an in vitro study, Cisplatin treat-
ment has increased the lipid peroxidation in human erythro-
cytes [64].
In conclusion it can be stated that (1) tested alkylating
agents EMS and MMS induced chromatid type of aberrations
in diabetic mice in a dose dependent manner, (2) methylating
agent (MMS) was a more potent inducer of chromatid type
aberrations than ethylating (EMS), (3) diabetic mouse is more
resistant than non diabetic to alkylating agents and (4) the
tested agents altered the analyzed biochemical parameters such
as catalase, glycogen and MDA.
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